





Image and Performance Enhancing Drugs

Glasgow 22nd March 2017

The range of IPEDs, user populations and motivations for use

Jim McVeigh

Director

Public Health Institute










Reproduced from www.ifbb.ru

dream plan achieve







158 lbs

175 lbs






The Drugs – anabolic steroids





Testosterone






Berthold 1849






Testosterone production



The Benefits of Optimal Testosterone



Man with Optimal Testosterone

Man with Deficient Testosterone





Definition of anabolic steroids

Mimic the effects of testosterone

Testosterone - anabolic & androgenic

Anabolic - growth & development of tissue

Androgenic - secondary male sexual characteristics

Not to be confused with corticosteroids






Clinical uses

- Aplastic anaemias
- Muscle wasting
 - Trauma/burns
 - •HIV/AIDS
- Post menopausal osteoporosis
- HRT for men
- Delayed male puberty
- Male contraceptive
 - Rarely indicated or used





The effect of anabolic steroids on testosterone production



Time



Testastan

Depot

Interterent Opposer





Use of drugs by male anabolic steroid injectors

0-4	36%	141
5+	32%	128
Median (IQR)	4 (8	3)
Not reported	32%	126
	57%	226
	23%	92
	15%	60
	20%	78
	9%	37
	6.6%	26
Oral phosphodiesterase type 5 inhibitor (PDE5i; "Viagra/Calias") Oral other image and performance enhancing drug (inc. Diuretics,		
	86%	340
	32%	128
	16%	62
	5.6%	22
	8.6%	34
Injected other image and performance enhancing drug (inc. ethryopoetin,		
Use of other illicit drugs Ever injected illicit drug other than an image and performance enhancing drug.		
	46%	181
	12%	47
	5+ Median (IQR) Not reported	5+

(Hope et al. 2013)





The growth of growth hormone

Author/ year Published	Sample	Growth hormone use
Korkia & Stimson Great Britain (1993)	110 anabolic steroid user interviews	2.7% (3/110) of those currently reporting anabolic steroid use also reported use of growth hormone in the past 6 months. Users were all male.
Lenehan et al. North West (1996)	386 interviews	57% (22/386) reported use of growth hormone in the past 6 months.
McVeigh et al Merseyside (2007)	85 anabolic steroid users interviews	21.2% reported use of growth hormone in the last 12 months
McVeigh et al Liverpool (2008)	27 anabolic steroid users at NSPs and Snowball sampling	29.6% reported lifetime use of growth hormone, with 11.1% reporting current use.
Hope et al England & Wales (2013)	395 IPED users at 19 NSPs	32% injected growth hormone in previous year






Post Cycle Therapy (PCT)






Post Cycle Therapy







Post Cycle Therapy







New,
Emerging and
Re-emerging Substances





Pegylated Mecano Growth Factor A long acting MGF similar to IGF-1





Growth Differentiation Factor 8 a myostatin inhibitor.

FST

Possibly Follistatin –myostatin antagonist

Sermorelin (GHRH 1-29) Stimulates growth hormone release








Weight loss drugs





盐酸克

也性安代管炎所至的对面 建原制 口服。一次1片,一日以秦

















Dinitrophenol (DNP)

'No dieting... No self-denial... No strenuous exercises... You can have the slender figure of Youth'.

'Literally burns the fat away'.

'Sounds too good to be true? Yet it is true'

Unpredictable responses & narrow therapeutic window

In just 2 years, 160 reported cases of cataracts and at least 10 deaths

Metabolic poison



Advert for Dilux-Redusols containing dinitrophenol, 1936.





Dinitrophenol (DNP)



















Melanotan










LIVERPOOL JOHN MOORES UNIVERSITY








Location: @ /Melanotan 2/Melanotan II 20mg Package

PRODUCT INFORMATION





Melanotan 2 - 20 mg Package

Includes 2 needles/wipes to get you started.

Sale Items

Melanotan 7 200ma Parkage

Each 10mg vial contains 10 injections.

opular Products	
elanotan II 10mg	
eedes 10 Pack	
elanotan II 20mg Package	
lelanotan II 30mg Package	
terlie Wipes 10 Pack	
velanotan 2 50mg package + 1 sk	free
iamond Labs ECA 30+ (EPH 25+	
ternative. Much Stronger)	
acteriostatic Water 30ml	
botrim 30 Tabs	
Manotan Nasal 2 Pack	
Melanotan Nasal 1 Pack	
lelanotan 2 100mg Package	
uy PT-141 Nasal Spray Incre	ase
nxual arousal bremelanotide	
HRP-6	
educTrim 15mg 30 Day Course	
elanotan 30mg + Free Kit	
IBOTRIM 90 TABS	
JC-1295	
T - 141 Injections	
dmin Kit 10mg	





(Novel) Psychoactive Substances





Gammahydroxybutyrate (GHB)





Scotland Yard probes 58 GHB-related deaths after Stephen Port killings

JUSTIN DAVENPORT CRIME EDITOR | 22 hours ago



























Phenibut







- Phenibut is a derivative of the naturally occurring inhibitory neurotransmitter γ-aminobutyric acid (GABA) - the parent structure of a phenethylamine.
- Discovered and introduced into clinical practice in Russia in the 1960s for its anxiolytic and reported nootropic (cognition enhancing) effects.
- It acts as a GABA-mimetic at GABAB and to some extent at GABAA receptors.





Reported drug use


Group	Drugs/Examples
Analgesics/anti-inflammatory drugs/opioids	Acetaminophen, aspirin, Ben-Gay, benoxaprofen, codeine, corticosteroids, heroin, hydrocodone, lidocaine, muscle oil (synthol) and muscle relaxing drugs, nalbuphine/nubain, naproxen, oxycodone, phenylbutazone, piroxicam
Anti-oestrogens	Aminogluthimide, aromatase inhibitors, clomiphene/clomid, proviron, tamoxifen
Cardiovascular drugs	Beta-2-agonists, beta-blockers, epinephrine, captopril, carvedilol, digoxin, thiazides, torsemide
Central nervous system inhibitors	Alcohol, benzodiazepines, buprenorfin, cannabinoids, hydrocodone, diazepam, gamma hydroxybutyrate (GHB), heroin, ketamine, oxycodone
Central nervous system stimulants	Amphetamine/meth, amyl nitrate, caffeine, cocaine, ephedrine, mephedrone, yohimbine
Cosmetic drugs	Anti-acne drugs, esiclene, melanotan I, suntan pills, thiomucase
Dietary/nutritional supplements	Calcium, choline and inositol
Diuretics	Furosemide, hydrochlorothiazide, spironolactone
Fat burning/weight loss drugs	2,4-dinitrophenol, anti-oestrogens, amphetamine/meth, beta blockers, bronchodilators, caffeine, chromium picolinate, clenbuterol, cocaine, conjugated linoleic acid, ephedrine, gamma hydroxybutyrate (GHB), growth hormone, hydrochlorothiazide insulin, insulin-like growth factor (IGF-1), laxatives, liothyronine, melanotan II, spironolactone, teroxin (T3), thiomucase, thyroxine, triacana, yohimbine
Muscle/strength-enhancement drugs (non- hormone)	Amphetamine/meth, anti-catabolics/glutamine, bronchodilators, chromium picolinate, clenbuterol, cocaine, creatine, ephedrine, herbal products, hydroxocobal amin (B12), melanotan II, myoblasts, muscle oil (synthol), protein powder, recovery drinks
Muscle/strength-enhancement hormones [†]	Daonil, dehydroepiandrosterone (DHEA), erythropoietin (EPO), genotropine, growth hormone, growth hormone releasing peptide, human chorionic gonadotropin (hCG), insulin-like growth factor 1 (IGF-1), insulin, levodopa, mechano growth factor, pregnyl, prohormones, proviron, somatotropine
Recreational drugs	Alcohol, cannabinoids, amphetamine/meth, caffeine, cocaine, hallucinogens, lysergic acid diethylamide (LSD), tobacco
Sexual enhancement drugs	Anti-oestrogens, human chorionic gonadotropin (hCG), melanotan II, phosphodiesterase-5 inhibitor (PDE5i), sildenafil, viagra/cialis, yohimbine

(Sagoe et al, 2015)





Global Drug Survey 2015 (89,509 responses)







Global Drug Survey – 993 steroid users

Drug	Used in last 12 months	Lifetime use
Cannabis	63.1	87.8
Other drugs *	44.6	71.4
Ecstasy	41.8	61.3
Cocaine	38.7	61.3
Amphetamines	20.6	49.1
LSD	18.1	41.1
Benzodiazepines	28.2	34.8
NPS	14.0	31.0
Opiates	15.3	30.0

^{*} Including magic mushrooms, poppers, nitrous, ketamine and GHB

^{*} Zahnow et al (in press)





The population(s) of users






The use of a chemical that affects the processes of the mind or body to make greater in value, beauty or effectiveness.





Historical context









Marmola



SHE WAS TOO FAT

And then she made up her mind to get thin and did, without hard exercise or starvation diet

Nobody loves a fat girl—but why mope about it when you can so easily get rid of that excess fat by means of a tried and true corrective, known and recommended by physicians the world over?

Many years ago medical science discovered that obesity—when an abnormal condition—is caused by the lack of an important element which the body normally supplies.

the body normally supplies.

That element—which is the chief ingredient of Marmola—has since been prescribed to thousands of overweight women, with amazingly beneficial results. It is taken with their meals, They do not wear themselves out with exercising, do not starve themselves, nor drain their systems with drastic purgatives. Yet day by day they have felt lighter, more alert, more energetic. Soon they find their weight satisfactory.

The excess fat has simply slipped away, revealing the trim and slender figure underneath.

Sounds like a miracle, but thousands of women who have taken Marmola as directed — 4 tablets a day—might well tell you it's a demonstrated fact. Indeed, since 1907, more than 20 million packages of Marmola have been purchased—proof positive that nothing succeeds like success. Marmola is put up by one of the leading medical laboratories of America.

Start today! You will soon experience Marmola's benefits. When you have gone far enough, stop taking Marmola. And you will bless the day when you first discovered this marvelous reducing agent!

Marmola is on sale by all dealers
—from coast to coast.

'Is fatness....a social offence?'

'Every over-fat person should try it'.

'Know once again the joy of a beautiful, slender figure and make Summer days happy days'.

'When reducing, it is of paramount importance to use a scientific treatment'.

Laxatives & thyroid extract

Between 1908 and 1940 Marmola was advertised more than 200 times in the Daily Mirror





Musculature Anabolic steroids, growth hormones

Weight loss Rimonabant, sibutramine, DNP

Skin & hair Mercury creams, melanotan II, Latissse

Sexual behaviour Sildenafil, bremelanotide

Cognitive function Methylphenidate and modafinil

Mood & Behaviour SSRI, benzodiazepines Beta blockers






Prevalence of anabolic steroid use





Adults reporting anabolic steroid use in last year/ever



		'V' 'V'	\V- \V-
Drug (2014/15)	Last year	Ever	
Anabolic steroids	73,000	293,000	
Heroin	27,000	223,000	CSEW, 2015




Proportion of boys using drugs in the last year, 2010

Type of drugs taken in the last year	Age 11 years	12 years	13 years	14 years	15 years	Total
	96	96	%	96	96	96
Cannabis	0.3	0.5	5.1	10.4	22.2	8.8
Any stimulants	0.8	0.5	1.7	3.4	5.0	2.5
Cocaine	0.1	0.2	0.9	1.1	1.5	0.8
Crack	0.1	0.1	0.5	0.5	0.7	0.4
Ecstasy	0.1	0.4	0.4	0.9	1.9	0.8
Amphetamines	0.1	0.1	0.9	0.9	1.1	0.7

1	l1 years	12 years	13 y	years	1	4 yea	ars	15 ye	ars	Total	
Anabolic C steroids).1	0.2	0.3		0	.9		0.2		0.3	
	or so Trans	, gas, aerosols alvents cuillisers	2.7 0.4 0.1	3.0 0.2 0.2	2.5 0.3 0.3	4.5 0.4 0.9	3.3 0.4 0.2	3.2 0.3 0.3			
	Othe	r drugs	0.1	0.1	0.3	0.2	0.9	0.4			
	Any		0.1 4.0	0.5 4.1	2.2 8.7	2.7 16.1	4.9 26.5	2.3 13.0			
	volat	drug (excluding tile substances)	1.4	1.3	6.5	12.8	24.7	10.6			
NatCen, 2012	(boy:	hted bases	565 551	771 754	735 716	707 712	868 926	3646 3659			

'All' & 'new' clients attending agency based NSPs in Cheshire & Merseyside (1991 to 2011)



Year of Presentation/Attendance

Proportion of NSP clients using enhancement drugs in the North of England

Middlesbroug	;h	67%
Kirklees		60%
Sheffield		62%
Newcastle		52%
Sunderland		60%
Bradford		41%
Halton		86%
Liverpool		83%
Sefton		43%
St Helens		34%
Warrington		86%
Wirral		77%
Manchester		60%
Bolton		52%

Contents lists available at ScienceDirect



Annals of Epidemiology

Annals Epidemiology

journal homepage: www.annalsofepidemiology.org

Review article

The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis

Dominic Sagoe MPhil, PhD Cand ^{a,*}, Helge Molde PhD ^b, Cecilie S. Andreassen PhD ^{a,c}, Torbjørn Torsheim PhD ^a, Ståle Pallesen PhD ^a

ARTICLE INFO

Article history: Received 5 November 2013 Accepted 23 January 2014 Available online 30 January 2014

Keywords: Steroids Prevalence Epidemiology Meta-analysis Regression Systematic review

ABSTRACT

Purpose: To estimate the global lifetime prevalence rate of anabolic-androgenic steroid (AAS) use and investigate moderators of the prevalence rate.

Methods: A meta-analysis and meta-regression analysis was performed using studies gathered from searches in PsycINFO, PubMed, ISI Web of Science, and Google Scholar among others. Included were 187 studies that provided original data on 271 lifetime prevalence rates. Studies were coded for publication year, region, sample type, age range, sample size, assessment method, and sampling method. Heterogeneity was assessed by the I^2 index and the Q-statistic. Random effect-size modeling was used. Subgroup comparisons were conducted using Bonferroni correction.

Results: The global lifetime prevalence rate obtained was 3.3% (95% confidence interval [CI], 2.8–3.8; $l^2 = 99.7$, P < .001). The prevalence rate for males, 6.4% (95% CI, 5.3–7.7, $l^2 = 99.2$, P < .001), was significantly higher ($Q_{bet} = 100.1$, P < .001) than the rate for females, 1.6% (95% CI, 1.3–1.9, $l^2 = 96.8$, P < .001). Sample type (athletes), assessment method (interviews only and interviews and questionnaires), sampling method, and male sample percentage were significant predictors of AAS use prevalence. There was no indication of publication bias.

Conclusion: Nonmedical AAS use is a serious widespread public health problem.

© 2014 Elsevier Inc. All rights reserved.

Introduction

Anabolic-androgenic steroids (AAS) are a group of hormones that include the natural male hormone, testosterone, together with sportspeople [8] and those who use AAS for either occupational or aesthetic purposes [7,9].

In the short-term, AAS use seems to have few serious medical consequences, but in the long-term, it has generally been associated

^a Department of Psychosocial Science, University of Bergen, Bergen, Norway

^bDepartment of Clinical Psychology, University of Bergen, Bergen, Norway

^cThe Competence Center, Bergen Clinics Foundation, Bergen, Norway





Motivations for use





Motivations for IPED use

Motivation	Motivation n (%) n=663	Main goal n (%) n=613
To gain muscle	588 (89)	377 (62)
To get stronger	426 (64)	68 (11)
To lose fat	323 (49)	55 (9.0)
To get fitter	205 (31)	36 (5.9)
To improve endurance or stamina	144 (22)	13 (2.1)
To get faster	90 (14)	2 (0.3)
To increase sex drive	57 (8.6)	5 (0.8)
To get a tan	30 (4.5)	0
To reduce wrinkles	30 (4.5)	0
Other	-	57 (9.3)

Bates & McVeigh, 2016



Quotes



'I feel more alive than I ever have and happier than I ever have.' (Korkia & Stimson, 1993)

'Steroids have allowed me to get a decent body which means more work. If there was another option which would get you the same results safely, of course I would use it.' (Korkia & Stimson, 1993)

'I started using [steroids] to build up my muscles and look better. In the group of lads I hang around with, the bigger you are the more respected you are and at my local gym everyone was doing it.' (Flanagan, 2007)

It's all about the way you look.' (Gilliver, 2007)

"[Bodybuilding is] the purest form of sport ... no external influences or arbitrary rules, the results are purely down to myself."

(Personal communication from steroid user, 2004)






"The day after the first subcutaneous injection, and still more after the two succeeding ones, a radical change took place in menervous energy has been increased in every way...ability to do intellectual work has been increased in every way...."

The control of the co

Brown Sequard, 1889

"It's chemical crutches. It's borrowed manhood. Its borrowed time. But just the same, its what makes bulls bulls."



de Kruif, 1945






"It's like you could run through a wall, and shag anything on the other side"

(Kimergård, 2009)





Typology of anabolic steroid user



Christiansen et al, 2016






and finally...

Don't believe everything you read.



muscle mass.






the subject below gained a stunning **27 pounds of lean muscle mass** and slash his bodyfat from 23% to 5.7% within just 49 days...







The strange case of GHRP-6



"We aim for a high standard...."













Jim McVeigh Director

Public Health Institute Liverpool John Moores University

0151 231 4512 j.mcveigh@ljmu.ac.uk